

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT8103542

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JONATHAN SCHOENFELD	07/25/2023
KAI WUCHERPFENNIG	07/25/2023
RECEIVING PARTY DATA	
Name:	DANA-FARBER CANCER INSTITUTE, INC.
Street Address:	450 BROOKLINE AVENUE
City:	BOSTON
State/Country:	MASSACHUSETTS
Postal Code:	02215-5450
PROPERTY NUMBERS Total: 5	
Property Type	Number
Application Number:	63277924
Application Number:	63317337
Application Number:	63342415
PCT Number:	US2022049556
Application Number:	17984647
CORRESPONDENCE DATA	
Fax Number:	(617)632-6800
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	617-632-5936
Email:	anshul_mehra@dfci.harvard.edu , jasmine_lo@dfci.harvard.edu , gunel_hajiyeva@dfci.harvard.edu , IP_Docketing@dfci.harvard.edu
Correspondent Name:	ANSHUL MEHRA
Address Line 1:	450 BROOKLINE AVENUE
Address Line 4:	BOSTON, MASSACHUSETTS 02215-5450
NAME OF SUBMITTER:	ANSHUL M. MEHRA
SIGNATURE:	/Anshul M. Mehra/
DATE SIGNED:	08/09/2023
Total Attachments: 5	
source=3122 Patent family-executed#page1.tif	

source=3122 Patent family-executed#page2.tif
source=3122 Patent family-executed#page3.tif
source=3122 Patent family-executed#page4.tif
source=3122 Patent family-executed#page5.tif

DFCI No.: 3122.P01US; 3122.P02US; 3122.P03US; 3122.W01WO; 3122.N01US; 3122.N01AU;
3122.N01AR; 3122.N01TW

Atty Nos.: TTC-01060; TTC-01061; TTC-01062; TTC-01025; TTC-01001; TTC-01040; TTC-
01037; TTC-01070

ASSIGNMENT

We, JONATHAN SCHOENFELD and KAI WUCHERPFENNIG, the undersigned and hereinafter referred to as the **ASSIGNORS**, for good and valuable consideration, the receipt of which is hereby acknowledged, confirm that we have sold and assigned and do hereby assign, sell, and transfer to DANA-FARBER CANCER INSTITUTE, INC., with offices at 450 Brookline Avenue, Boston, MA, 02215, and its successors and assigns, hereinafter referred to as the **ASSIGNEE**, our entire right, title, and interest for the United States and all countries in and to the following:

(a) any and all inventions, discoveries, and improvements described in:

U.S. Application No. **63/277,924**, titled MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF, filed on November 10, 2021,

U.S. Application No. **63/317,337**, titled MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF, filed on March 7, 2022,

U.S. Application No. **63/342,415**, titled MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF, filed on May 16, 2022,

PCT Application No. **PCT/US2022/049556**, titled MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF, filed on November 10, 2022,

U.S. Application No. **17/984,647**, titled MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF, filed on November 10, 2022,

Argentine Application No. **20220103089**, titled MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF, filed on November 10, 2022,

Australian Application No. **2022268347**, titled MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF, filed on November 10, 2022,

Taiwanese Application No. **111143030**, titled MAGEA1 IMMUNOGENIC PEPTIDES, BINDING PROTEINS RECOGNIZING MAGEA1 IMMUNOGENIC PEPTIDES, AND USES THEREOF, filed on November 10, 2022,

DFCI No.: 3122.P01US; 3122.P02US; 3122.P03US; 3122.W01WO; 3122.N01US; 3122.N01AU;
3122.N01AR; 3122.N01TW

Atty Nos.: TTC-01060; TTC-01061; TTC-01062; TTC-01025; TTC-01001; TTC-01040; TTC-
01037; TTC-01070

hereinafter referred to as the **APPLICATION(S)**;

- (b) the **APPLICATION(S)** and all other applications that may be made therefor (including continuations; continuations-in-part; divisionals; international applications; national, including foreign national, applications; regional applications; and revivals) and all patents, utility models, design registrations, other rights of exclusion, and inventors' certifications therefor (including reissues, extensions, and renewals), based in whole or in part on any of the foregoing, in all countries, regions, and territories and under every treaty or convention;
- (c) the right to claim priority based on and the benefit of the filing date of the above applications; and
- (d) the right to pursue, collect, and retain damages and any other remedies arising from any past, present, or future infringement of the above patents, utility models, design registrations, rights of exclusion, and inventors' certifications and any other rights assigned by this **ASSIGNMENT**.

The above is intended to expressly grant the recited rights, titles, and interests in the People's Republic of China, the Republic of Korea, and Japan.

For the same consideration, we authorize the **ASSIGNEE** to apply for and pursue protection for procurement, maintenance, enforcement, and defense of any or all of the above inventions, discoveries, and improvements and any other rights, interests, and titles assigned by this **ASSIGNMENT** in all countries, regions, and territories in our names or in the **ASSIGNEE'S** name.

For the same consideration, we will communicate all known facts relating to the above applications, patents, utility models, design registrations, rights of exclusion, and inventors' certifications to the **ASSIGNEE** or, at the request of the **ASSIGNEE**, to other parties; we will execute and provide all oaths, declarations, statements, testimony, assignments, powers of attorney, applications, and documents; and we will perform all other lawful acts necessary or desirable to fully secure to the **ASSIGNEE** the above rights, titles, and interests.

We represent and warrant that we have the right and power to make this **ASSIGNMENT** and that we have not made and will not make any other assignment that conflicts with this **ASSIGNMENT**. We covenant with the **ASSIGNEE** that no assignment, grant, mortgage, or other agreement affecting this **ASSIGNMENT** has been made or will be made to others by us. We authorize any attorney of record for the above-identified application(s) to insert the application number(s), filing dates and filing country(ies) into this document when available.

DSCI No.: 3122.P01US; 3122.P02US; 3122.P03US; 3122.W01WO; 3122.N01US; 3122.N01AU;
3122.N01AR; 3122.N01TW

Atty Nos.: TTC-01060; TTC-01061; TTC-01062; TTC-01025; TTC-01001; TTC-01040; TTC-
01037; TTC-01070

at Boston, MA
(City, State)
on this 25 day of July, 2023
State of Massachusetts
County of Suffolk


JONATHAN SCHOENFELD

This 25th day of July, 2023, before me personally came the above-named JONATHAN
SCHOENFELD, who executed the forgoing instrument in my presence and who acknowledged
to me that this instrument was by JONATHAN SCHOENFELD's own free will.

[SEAL]




NOTARY PUBLIC
My commission expires: May 15, 2026

DFCI No.: 3122.P01US; 3122.P02US; 3122.P03US; 3122.W01WO; 3122.N01US; 3122.N01AU;
3122.N01AR; 3122.N01TW

Atty Nos.: TTC-01060; TTC-01061; TTC-01062; TTC-01025; TTC-01001; TTC-01040; TTC-
01037; TTC-01070


at Boston, Massachusetts
(City, State)
on this 25th day of July, 2023
State of Massachusetts
County of Suffolk


KAI WUCHERPFENNIG

This 25th day of July, 2023, before me personally came the above-named KAI
WUCHERPFENNIG, who executed the forgoing instrument in my presence and who
acknowledged to me that this instrument was by KAI WUCHERPFENNIG's own free will.


NOTARY PUBLIC
My commission expires:

[SEAL]




DFCI No.: 3122.P01US; 3122.P02US; 3122.P03US; 3122.W01WO; 3122.N01US; 3122.N01AU;
3122.N01AR; 3122.N01TW

Atty Nos.: TTC-01060; TTC-01061; TTC-01062; TTC-01025; TTC-01001; TTC-01040; TTC-
01037; TTC-01070

ACKNOWLEDGMENT OF ASSIGNEE:

I hereby acknowledge the foregoing executed ASSIGNMENT on behalf of DANA-FARBER
CANCER INSTITUTE, INC.



Anshul Mehra, Intellectual Property Counsel

8/8/2023

Date: